Tecentriq meets PFS endpoint in first-line TNBC

Genentech Inc. said Tecentriq atezolizumab met the co-primary endpoint of improving progression-free survival (PFS) in the Phase III IMpassion130 trial as first-line treatment of triple-negative breast cancer (TNBC). The Roche (SIX:ROG;

Read the full 312 word article

User Sign In